#DyeVert - Twitter Hashtag

about 3 years ago

📑 The REMEDIAL IV aims to test whether the #DyeVert system is effective in #CM minimization and reducing #AKI rate in #ACS patients undergoing urgent invasive procedures.🔍 ➡️ https://t.co/SwCNTfrPkp

MyJSCAI's tweet photo. 📑 The REMEDIAL IV aims to test whether the #DyeVert system is effective in #CM minimization and reducing #AKI rate in #ACS patients undergoing urgent invasive procedures.🔍

➡️ https://t.co/SwCNTfrPkp https://t.co/YTzw41Opme

0

2

0

956

Giuseppe Biondi-Zoccai @gbiondizoccai

about 5 years ago

"Contrast media volume reduction obtained by the DyeVert system is an effective strategy to prevent AKI in ACS patients undergoing invasive procedure" https://t.co/cuuGTU1pJe #DyeVert

gbiondizoccai's tweet photo. "Contrast media volume reduction obtained by the DyeVert system is an effective strategy to prevent AKI in ACS patients undergoing invasive procedure"
https://t.co/cuuGTU1pJe
#DyeVert https://t.co/6zK3I4Ovmr

0

2

0

1

0

Osprey Medical Investors @OspreyMed_IR

almost 7 years ago

$OSP released its #Appendix4C for 3Q 2019, with a 48% increase in #DyeVert unit sales vs PCP. GPO sales contributed strongly to overall 3Q sales, with 2,083 units in 3Q and a 173% PCP increase. Full update at: https://t.co/C23RB5PAX1

OspreyMed_IR's tweet photo. $OSP released its #Appendix4C for 3Q 2019, with a 48% increase in #DyeVert unit sales vs PCP. GPO sales contributed strongly to overall 3Q sales, with 2,083 units in 3Q and a 173% PCP increase. Full update at: https://t.co/C23RB5PAX1 https://t.co/GcrqZKjJhE

0

3

0

Osprey Medical Investors @OspreyMed_IR

almost 7 years ago

The market opportunity for $OSP stands at US$1.65B per-year in the US and Western EU, w/ 3.2M procedures per-year for #DyeVert Plus and 3.5M procedures for #DyeTect. Learn more about Osprey's commercial approach in its latest presentation: https://t.co/3IQd50UYoo

OspreyMed_IR's tweet photo. The market opportunity for $OSP stands at US$1.65B per-year in the US and Western EU, w/ 3.2M procedures per-year for #DyeVert Plus and 3.5M procedures for #DyeTect. Learn more about Osprey's commercial approach in its latest presentation: https://t.co/3IQd50UYoo https://t.co/hlcIHZDCBo

0

2

0

Osprey Medical Investors @OspreyMed_IR

almost 7 years ago

The Osprey Medical team is in San Francisco at TCT.19 this week. Stop by and see what is new at booth # 1728. @bekindtokidneys #cardiorenal #dyevert #ospreymed $OSP https://t.co/6H9NKa0qwW

0

4

0

Osprey Medical Investors @OspreyMed_IR

about 7 years ago

Osprey's #DyeVert system received @PremierHA's Breakthrough Technologies Award in 2018 and $OSP signed a purchasing agreement with the GPO. Learn more about Premier: https://t.co/hVJC27gZf9

OspreyMed_IR's tweet photo. Osprey's #DyeVert system received @PremierHA's Breakthrough Technologies Award in 2018 and $OSP signed a purchasing agreement with the GPO. Learn more about Premier: https://t.co/hVJC27gZf9 https://t.co/yDgNeq3riT

0

4

1

0

Osprey Medical Investors @OspreyMed_IR

about 7 years ago

Back in July $OSP had its first ever DyeVert EZ case in Australia, at Sunshine Hospital Melbourne. The patient received 42% less contrast using the #DyeVert system. Thanks to Dr Stub and the cath lab staff for an excellent first case #ASX

OspreyMed_IR's tweet photo. Back in July $OSP had its first ever DyeVert EZ case in Australia, at Sunshine Hospital Melbourne. The patient received 42% less contrast using the #DyeVert system. Thanks to Dr Stub and the cath lab staff for an excellent first case #ASX https://t.co/tphRrpHqVJ

0

4

1

0

Lydia N @lydiansc88

about 7 years ago

Dr Navin Chandra @nav4879 & the team at #WexhamCardiology thank you for trying #DyeVert by @OspreyMed #Bekindtokidneys

0

9

0

Osprey Medical Investors @OspreyMed_IR

about 7 years ago

Read our $OSP June 2019 investor newsletter released today. Articles include a message from CEO Mike McCormick, recent data supporting kidney care protocol including #DyeVert to lower cost of care, and Osprey's direct-to-patient awareness campaign https://t.co/WxSH2C2j6l

0

4

2

0

Osprey Medical Investors @OspreyMed_IR

about 7 years ago

Data from 4 hospitals including @UnivHealthSys and @MetroHosp210 cardiac cath labs has shown up to a 75% reduction in AKI events, after guideline-driven kidney care protocols including $OSP #DyeVert were implemented for at-risk patients. https://t.co/IBqssrZhyY

OspreyMed_IR's tweet photo. Data from 4 hospitals including @UnivHealthSys and @MetroHosp210 cardiac cath labs has shown up to a 75% reduction in AKI events, after guideline-driven kidney care protocols including $OSP #DyeVert were implemented for at-risk patients. https://t.co/IBqssrZhyY https://t.co/0tBsMLYmz6

0

4

1

0

Osprey Medical Investors @OspreyMed_IR

over 7 years ago

Today $OSP announced the launch of DyeMINISH™, a global patient registry to evaluate the ongoing safety and performance of the #DyeVert system. Read more: https://t.co/GWxV5bXrVp

OspreyMed_IR's tweet photo. Today $OSP announced the launch of DyeMINISH™, a global patient registry to evaluate the ongoing safety and performance of the #DyeVert system. Read more: https://t.co/GWxV5bXrVp https://t.co/2Rr9htKSOQ

0

2

1

0

Brian Haines @BrianHainesSAIF

over 7 years ago

Another complex case from a San Antonio Cardiology Leader and member of the SAIF Executive Committee. Great use of #dyevert with terrific opacification and a creatinine drop post procedure. @JamilMalikSTCC @cardio_renal @ChadRCCV @SAHealth210 @ProtectedPCI @OspreyMed